Well, I suppose the longer we continue to see no "Change in Director Interests" or "Substantial Shareholder Holdings" notices - we MAY be able to draw at least a skerrick of some much needed positivity.
IMO, anyone who can't afford to lose any money shouldn't be in this type of company in the first place. A start-up biotech is a risky business and it is always going to take time to get a "square wheel" underway with growing momentum. So, I really can't understand why anyone would keep selling at this time. And, who enjoys trying to catch a falling knife?
If the company is still around come November, and things are the same, I think I will definitely be making the effort to jump the ditch and attend the AGM. The last time I attended, Leverage was the only attending shareholder that asked what could be termed a "challenging" question of the Board. I am hoping that might change this year.
CDY Price at posting:
20.0¢ Sentiment: None Disclosure: Held
